PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL. (June 2017)